The presence of memory T-cells recognizing peptide epitopes from SARS-CoV-2 might protect us from severe diseases due to infection caused by the new variants of coronavirus. CD8+ and CD4+ T-cells recognize peptide epitopes that are presented by HLA Class-I and II, respectively. CD8+ T-cells kill the infected cells and CD4+ T-cells orchestrate and help other immune cells such as B-cells to produce antibodies. Immunoinformatic analysis of the entire SARS-CoV-2 proteome of Wuhan Hu-1 was conducted using netMHCpan(1) and netMHCIIpan(2) to predict T-cell epitopes presented by HLA Class-I and Class-II alleles, respectively. As the aim is to study T-cell responses to SARS-CoV-2 in Indonesian population, the HLA alleles which have at least 5% frequency in the population were chosen(3). Peptides that fulfil 2% rank threshold as binder were checked for sequence conservancy in Delta and Omicron variants using IEDB conservancy analysis tool(4), and conserved peptides were chosen for synthesis. Several other criteria were applied such as cysteine containing peptides were not selected for synthesis and ORF1ab peptides that span the cleavage site of the 2 consecutive non-structural proteins were also not selected. The immunoinformatic analysis generated 111 peptides presented by HLA Class-I and 34 peptides presented by HLA Class-II. Initial ELISPOT assay was conducted to test the immunogenicity of 10 HLA Class-II peptides. PBMC samples were collected from 5 study participants: 4 with history of SARS-CoV-2 infection and COVID-19 vaccination and 1 without prior infection nor vaccination. Prior to the ELISPOT assay, the PBMC samples were stimulated with peptides for 12 days to expand the number of T-cells that recognize the peptides. IL-2 were added at day 2, 5, and 7. Six peptides, 3 of them are listed already in IEDB and 3 others are new, were positive in IFNγ-ELISPOT assay, indicating the presence of T-cell memory among the study participants.